Highlights of This Issue  2919

SPECIAL FEATURES

2921  New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer
Hans Prenen, Sabine Tejpar, and Eric Van Cutsem

2927  CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
Beverly A. Teicher and Simon P. Fricker

2932  Control of Tumorigenesis and Chemoresistance by the DEK Oncogene
Erica Riveiro-Falkenbach and María S. Soengas

2939  The Proapoptotic Molecule BLID Interacts with Bcl-XL and Its Downregulation in Breast Cancer Correlates with Poor Disease-Free and Overall Survival
Constantinos G. Broustas, Jeffrey S. Ross, Qifeng Yang, Christine E. Sheehan, Rebecca Riggins, Anne-Michelle Noone, Bassem R. Haddad, Françoise Seiller-Moiseiwitsch, Bhaskar V.S. Kallakury, Bruce G. Haffty, Robert Clarke, and Usha N. Kasid

2949  The Tumor Suppressor UCHL1 Forms a Complex with p53/MM2/ARF to Promote p53 Signaling and Is Frequently Silenced in Nasopharyngeal Carcinoma
Lili Li, Qian Tao, Hongchuan Jin, Andrew van Hasselt, Fan Fong Poon, Xian Wang, Mu-Sheng Zeng, Wei-Hua Jia, Yi-Xin Zeng, Anthony T.C. Chan, and Ya Cao

2959  The Transcriptional Coregulator RIP140 Represses E2F1 Activity and Discriminates Breast Cancer Subtypes
Aurélie Docquier, Pierre-Olivier Harmand, Samuel Fritsch, Maia Channion, Jean-Marie Darbon, and Vincent Cavailles

2971  Chromosomal and MicroRNA Expression Patterns Reveal Biologically Distinct Subgroups of 11q- Neuroblastoma

2979  Telomere Maintenance and DNA Damage Responses during Lung Carcinogenesis
Sylvie Lantuejoul, Christophe Raynaud, Dimitri Salameire, Sylvie Gazzieri, Denis Moro-Sibilot, Jean-Charles Soria, Christian Brambilla, and Elizabeth Brambilla

2989  Assessment of the In vivo Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line–Derived Human Colorectal Cancer Xenograft Models
John J. Tentler, Erica L. Bradshaw-Pierce, Natalie J. Serkova, Kendra M. Hasebroock, Todd M. Pitts, Jennifer R. Diamond, Graham C. Fletcher, Mark R. Bray, and S. Gail Eckhardt

2999  Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian Cancer
IMAGING, DIAGNOSIS, PROGNOSIS

3011  Fibroblast Growth Factor Receptor 3 Mutation Analysis on Voided Urine for Surveillance of Patients with Low-Grade Non-Muscle-Invasive Bladder Cancer
Tahlita C.M. Zuiverloon, Madelon N.M. van der Aa, Theo H. van der Kwast, Ewout W. Steyerberg, Hester F. Lingma, Chris H. Bangma, and Ellen C. Zwarthoff

3054  Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2–Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors
Alain C. Mit, Chris H. Takimoto, Monica Mit, Anthony Tolcher, Kamalesh Sankhal, John Sarantopoulos, Manuel Valdivieso, Leslie Wood, Erik Rasmussen, Yu-Nien Sun, Z. Don Zhong, Michael B. Bass, NgocDiep Le, and Patricia LoRusso

3057  A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer
Andrew J. Armstrong, George J. Netto, Michelle A. Rudek, Susan Halabi, David P. Wood, Patricia A. Cree, Kelly Mundy, S. Lindsay Davis, Ting Wang, Roula Albadine, Luciana Schultz, Alan W. Partin, Antonio Jimeno, Helen Fedor, Phillip G. Febbo, Daniel J. George, Robin Gurganus, Angelo M. De Marzo, and Michael A. Carducci

CANCER THERAPY: CLINICAL

3019  A Phase I Study of 5-Fluorouracil/Leucovorin and Arsenic Trioxide for Patients with Refractory/Relapsed Colorectal Carcinoma
Bach Ardalan, Pochi R. Subbarayan, Yipsel Ramos, Michael Gonzalez, Anthony Fernandez, Dmitry Mezentsev, Isildinha Reis, Robert Duncan, Lisa Podolsky, Kelvin Lee, Mayra Lima, and Parvin Ganjei-Azar

3028  Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer
Tanya B. Dorff, Bryan Goldman, Jacek K. Pinski, Philip C. Mack, Primo N. Lara, Jr., Peter J. Van Veldhuizen, Jr., David I. Quinn, Nicholas J. Vogelzang, Ian M. Thompson, Jr., and Maha H.A. Hussain

3035  Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
Petri Nokisalmi, Sari Pesonen, Sophie Escutenaire, Merja Särköjoa, Mari Raki, Vincenzo Cerullo, Leena Laasonen, Ramon Alemany, Juan Rojas, Manel Cascallo, Kilan Guse, Maria Rajek, Lotta Kangasniemi, Elna Haavisto, Aila Karioja-Kallio, Päivi Hannuksela, Minna Oksanen, Anna Kanerva, Timo Joensuu, Laura Abstiainen, and Akseli Hemminki

3078  A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer
ABOUT THE COVER

BLID expression was found to be lost or decreased in several invasive ductal breast carcinomas (IDC). The cover image shows an example of BLID-negative IDC as determined by immunohistochemistry using a breast tumor tissue microarray. Lack of BLID was associated with poor prognostic factors and survival. For details, see the article by Broustas and colleagues on page 2939 of this issue.